MedPath

Marcus Maurer

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:3

Trial Phases

2 Phases

Phase 2:2
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 4
1 (33.3%)

Profiling Urticaria for the Identification of Subtypes

Completed
Conditions
Non-autoreactive Chronic Spontaneous Urticaria
Autoimmune Chronic Spontaneous Urticaria
Autoreactive, Non-autoimmune Chronic Spontaneous Urticaria
First Posted Date
2012-07-10
Last Posted Date
2015-07-28
Lead Sponsor
Marcus Maurer
Target Recruit Count
195
Registration Number
NCT01637116
Locations
🇩🇪

University of Berlin Charité, Berlin, Germany

Study on Mastocytosis for Rupatadine Treatment

Phase 2
Completed
Conditions
Mastocytosis
Interventions
Drug: Rupatadin
First Posted Date
2011-11-30
Last Posted Date
2016-11-03
Lead Sponsor
Marcus Maurer
Target Recruit Count
30
Registration Number
NCT01481909
Locations
🇩🇪

University Charité, Berlin, Germany

Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria

Phase 4
Completed
Conditions
Urticaria
Interventions
First Posted Date
2011-09-30
Last Posted Date
2011-10-03
Lead Sponsor
Marcus Maurer
Target Recruit Count
30
Registration Number
NCT01444196
Locations
🇩🇪

Department of Dermatology, Venerology and Allergology, Berlin, Germany

Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria

Phase 2
Terminated
Conditions
Chronic Urticaria
Interventions
Drug: Placebo
First Posted Date
2010-07-28
Last Posted Date
2016-12-26
Lead Sponsor
Marcus Maurer
Target Recruit Count
76
Registration Number
NCT01170949
Locations
🇩🇪

Charité University, Berlin, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.